Table A6.
HRs and 95% CIs for Development of Grade 3-5 Health Conditions at or After Age 35 Years, After Specific Therapy for Primary Cancer, Versus Siblings Both With and Without Weighting for Nonparticipation
| Therapy for Treatment of Primary Cancer | With Weights |
Without Weights |
||
|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |
| Surgery | ||||
| Any surgery | 5.1 | 4.2 to 6.2 | 5.0 | 4.1 to 6.1 |
| Surgery only | 1.8 | 1.2 to 2.7 | 1.8 | 1.2 to 2.7 |
| Nephrectomy | 3.3 | 2.0 to 5.3 | 3.1 | 1.9 to 5.1 |
| Splenectomy | 7.5 | 6.1 to 9.3 | 7.4 | 6.0 to 9.1 |
| Radiation | ||||
| Any radiation | 5.8 | 4.7 to 7.0 | 5.7 | 4.6 to 7.0 |
| Chest RT | 7.1 | 5.8 to 8.7 | 7.0 | 5.7 to 8.6 |
| CNS RT | 5.0 | 3.9 to 6.4 | 4.9 | 3.8 to 6.3 |
| Abdominal RT | 7.1 | 5.7 to 8.8 | 7.1 | 5.7 to 8.7 |
| Pelvic RT | 6.6 | 5.3 to 8.2 | 6.6 | 5.3 to 8.2 |
| No radiation | 2.6 | 2.0 to 3.3 | 2.6 | 2.0 to 3.3 |
| Chemotherapy | ||||
| Any chemotherapy | 4.9 | 4.0 to 6.1 | 4.9 | 4.0 to 6.0 |
| Cisplatin | 4.8 | 3.1 to 7.5 | 4.5 | 2.9 to 6.9 |
| Alkylator | 5.5 | 4.5 to 6.8 | 5.5 | 4.4 to 6.7 |
| Anthracycline | 4.7 | 3.7 to 5.9 | 4.6 | 3.7 to 5.8 |
| Methotrexate | 3.7 | 2.9 to 4.7 | 3.6 | 2.9 to 4.6 |
| Bleomycin | 7.0 | 5.3 to 9.4 | 6.9 | 5.1 to 9.2 |
| Combinations | ||||
| Chest RT + bleomycin | 9.3 | 6.7 to 13.0 | 9.1 | 6.5 to 12.7 |
| Chest RT + abdominal or pelvic RT | 7.8 | 6.3 to 9.6 | 7.7 | 6.2 to 9.5 |
| Abdominal or pelvic RT + alkylator | 6.9 | 5.5 to 8.7 | 6.9 | 5.5 to 8.6 |
| Chest RT + anthracyclines | 7.4 | 5.6 to 9.9 | 7.3 | 5.5 to 9.7 |
| Anthracyclines + an alkylator | 4.7 | 3.7 to 5.9 | 4.6 | 3.7 to 5.8 |
NOTE. Each row represents a separate multivariable model adjusted for sex and race, with age as the time scale. Models allow for multiple events and participants may have had a grade 3-4 event before age 35 years.
Abbreviations: HR, hazard ratio; RT, radiation therapy.